MedPath

Efficacy Study of Phytotherapy "Raylis" In Congestive Processes Of The Pelvic Organs (Prostatostasis)

Phase 3
Conditions
Congestive Processes Of The Pelvic Organs (Prostatostasis)
Erectile Dysfunction
Sexual Function
Interventions
Drug: "Raylis"
Other: standard prostatostasis therapy
Registration Number
NCT01866995
Lead Sponsor
The Clinic of Men's Health and Couple Longevity, Russia
Brief Summary

The purpose of this study is to investigate the efficacy of Phytotherapy "Raylis" (Ginseng Root Powder 50 mg, False Ginseng Root Powder 50 mg, Codonopsis Root Powder 50 mg, Astragalus Membranaceus Root Powder 50 mg, Epimedium Alpinum Herbal Extract 100 mg) In Congestive Processes Of The Pelvic Organs (Prostatostasis) In Congestive Processes Of The Pelvic Organs (Prostatostasis)

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
50
Inclusion Criteria
  • Age 20-60 years
  • Symptoms of prostatostasis lasting for at least 3 months during the past 6 months:
  • Pathological changes on uroflowmetry (maximum flow rate of less than 15 ml / s, average urinary flow rate of less than 12 ml / sec)
  • TRUS Prostate volume more than 22 ml at TRUS
  • TRUS picture of Prostatostasis
  • I-PSS 7-20
  • IIEF-5) - 12-21
Exclusion Criteria
  • Contraindications and limitations to use of the drug Raylis listed in the instructions for medical use *
  • Diabetes mellitus (type 1 and type 2, decompensation)
  • Neurogenic disorders (acute cerebral circulatory disorders, Alzheimer's disease, spinal cord injury)
  • A history of pelvic trauma
  • Patients who had undergone radical prostatectomy and other surgical interventions on the pelvic organs
  • Concomitant use of supplements to improve the erectile function, use of the anti-androgens, anti-depressants, finasteride.
  • Diagnosed BPH
  • Current participation in a clinical trial and / or study medication for 30 days prior to inclusion
  • Any form of substance abuse, mental disorder or condition which, in the opinion of the investigator, may complicate communication with the researcher.
  • The inability or unwillingness to comply with the scheme of visits according to protocol.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Raylis"Raylis"This arm (10 men with symptoms of prostatostasis) will get "Raylis" (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months
standard prostatostasis therapystandard prostatostasis therapyThis arm (20 men with symptoms of prostatostasis) will get the standard (pathogenetic) therapy of prostatostasis
Raylis plus standard prostatostasis therapy"Raylis"This arm (20 men with symptoms of prostatostasis) will get "Raylis" (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months together with standard prostatostasis therapy
Raylis plus standard prostatostasis therapystandard prostatostasis therapyThis arm (20 men with symptoms of prostatostasis) will get "Raylis" (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months together with standard prostatostasis therapy
Primary Outcome Measures
NameTimeMethod
TRUS prostate3 months
Secondary Outcome Measures
NameTimeMethod
Uroflowmetry3 months

Trial Locations

Locations (1)

Clinic Of Men's Health and Couple Longevity

🇷🇺

Moscow, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath